Systems, methods, and devices for adaptive cardiac therapy - Patents.com
External electrode devices and computing systems allow for non-invasive monitoring and adaptive cardiac therapy optimization, addressing the limitations of implantable devices by personalizing CRT configurations for improved cardiac synchrony and efficiency.
Patent Information
- Application Number
- JP2021542122
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-29
- Filing Date
- 2020-02-25
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-02-25
AI Technical Summary
Existing implantable medical devices (IMDs) for cardiac therapy lack the ability to provide personalized and adaptive cardiac resynchronization therapy (CRT) without invasive procedures, as they rely on implantable sensors and electrodes, which limit the ability to optimize pacing configurations based on individual patient-specific electrical and mechanical heart functions.
The use of external electrode devices and computing systems to non-invasively monitor electrical activity across the patient's torso, generating electrical inhomogeneity information (EHI) to determine optimal A-V and V-V intervals for biventricular and left ventricular pacing, allowing for adaptive cardiac therapy configurations tailored to individual patient needs.
Enables personalized and adaptive cardiac resynchronization therapy by optimizing pacing configurations based on patient-specific electrical and mechanical heart functions, improving cardiac synchrony and efficiency without the need for invasive implantation of sensors or electrodes.
Smart Images

Figure 0007577667000001 
Figure 0007577667000002 
Figure 0007577667000003
Abstract
Description
[Technical field]
[0001] The disclosure herein relates to systems, methods, and devices for configuring and using external electrode devices to deliver adaptive cardiac therapy. [Background technology]
[0002] An implantable medical device (IMD), such as an implantable pacemaker, cardioverter, defibrillator, or pacemaker-cardioverter-defibrillator-defibrillator, provides therapeutic electrical stimulation to the heart. The IMD may provide pacing to address bradycardia, or pacing or shocks to terminate tachyarrhythmias, such as tachycardia or fibrillation. In some cases, the medical device may sense the intrinsic depolarization of the heart, detect arrhythmias based on the intrinsic depolarization (or lack thereof), and control the delivery of electrical stimulation to the heart if an arrhythmia is detected based on the intrinsic depolarization.
[0003] IMDs may also provide cardiac resynchronization therapy (CRT), a form of pacing. CRT involves the delivery of pacing to the left ventricle, or to both the left and right ventricles. The timing and location of delivery of the pacing pulses to the ventricle(s) may be selected to improve the coordination and efficiency of ventricular contractions.
[0004] In addition to the implantable medical device itself, a system for implanting a medical device may include a workstation or other equipment that assists a physician or other technician in placing intracardiac leads at specific locations on or within the heart. In some cases, the equipment provides the physician with information regarding the electrical activity of the heart and the location of the intracardiac leads. Summary of the Invention
[0005] Exemplary systems and methods described herein may be configured to aid a user (e.g., a physician) in assessing and configuring cardiac therapies (e.g., cardiac therapies delivered to a patient during and / or after implantation of a cardiac therapy device). In one or more embodiments, the systems and methods may be described as non-invasive. For example, in some embodiments, the systems and methods may not require or include implantable devices, such as leads, probes, sensors, catheters, implantable electrodes, etc., for monitoring or acquiring multiple cardiac signals from the patient's tissue for use in assessing and configuring cardiac therapies delivered to the patient. Instead, the systems and methods may use electrical measurements made non-invasively, for example, using multiple external electrodes attached to the patient's skin around the patient's torso.
[0006] Exemplary systems and methods may be described as including the use of an external electrode device, or ECG belt, applied to the patient's torso to determine optimal synchrony during biventricular and left ventricular pacing. Optimal AV timing for each pacing configuration, e.g., biventricular pacing and left ventricular only pacing, across multiple heart rates may be identified based on electrical dyssynchrony metrics derived or generated from electrical activity monitored using the external electrode device across multiple heart rates. For example, an optimal pre-excitation interval for each configuration may be determined or calculated by subtracting the optimal AV timing from the patient's intrinsic AV conduction, which may be used to adaptively update the AV delay for pacing delivery based on periodically measuring the patient's intrinsic AV and subtracting the optimal pre-excitation interval. If the patient's intrinsic AV exceeds a certain absolute value (e.g., about 300 milliseconds (ms) to about 350 ms) or exceeds a certain threshold value (e.g., about 20 ms, about 30 ms, about 40 ms, etc.) compared to the baseline intrinsic AV, or the heart rate exceeds 100 bpm and the current pacing configuration is left ventricular only, the device can switch to biventricular pacing with optimal pre-excitation for the biventricular configuration. Furthermore, the device can be described as being programmed to a baseline based on which pacing configuration provides more synchrony for biventricular pacing or left ventricular only pacing. In this manner, the illustrated systems, methods, and devices can be described as providing a way to individualize adaptive cardiac resynchronization therapy with a patient-specific optimal pre-excitation interval and pacing configuration (biventricular pacing or left ventricular only pacing).
[0007] One exemplary system may include an electrode device including a plurality of external electrodes for monitoring electrical activity from tissue of a patient, and a computing device including a processing circuit and coupled to the electrode device. The computing device may be configured to monitor electrical activity of the patient's heart using one or more of the plurality of external electrodes during left ventricular-only pacing therapy delivered at a plurality of different AV intervals across a plurality of different heart rates and during biventricular pacing therapy delivered at a plurality of different AV and VV intervals across a plurality of different heart rates, and generate electrical inhomogeneity information (EHI) from the monitored electrical activity from the electrode device, the EHI being indicative of one or both of mechanical and electrical cardiac function. The computing device may be further configured to select an AV interval for the left ventricular-only pacing therapy for each different heart rate based on the EHI generated from the monitored electrical activity during the left ventricular-only pacing therapy, and to select AV and VV intervals for the biventricular pacing therapy for each different heart rate based on the EHI generated from the monitored electrical activity during the biventricular pacing therapy.
[0008] One exemplary method can include monitoring electrical activity of a patient's heart using one or more of a plurality of external electrodes during left ventricular-only pacing therapy delivered at a plurality of different AV intervals and during biventricular pacing therapy delivered at a plurality of different AV and VV intervals across a plurality of different heart rates, and generating electrical inhomogeneity information (EHI) from the monitored electrical activity from the electrode device, the EHI representing one or both of mechanical and electrical heart function. The method can further include selecting an AV interval of the left ventricular-only pacing therapy for each of the different heart rates based on the EHI generated from the monitored electrical activity during the left ventricular-only pacing therapy, and selecting AV and VV intervals of the biventricular pacing therapy for each of the different heart rates based on the EHI generated from the monitored electrical activity during the biventricular pacing therapy.
[0009] One exemplary implantable medical device can include a plurality of electrodes including an atrial pacing electrode, a left ventricular pacing electrode, and a right ventricular pacing electrode, a therapy delivery circuit operably coupled to the plurality of electrodes to deliver a cardiac therapy to the patient's heart, a sensing circuit operably coupled to the plurality of electrodes to sense electrical activity of the patient's heart, and a controller comprising a processing circuit operably coupled to the therapy delivery circuit and the sensing circuit. The controller can be configured to calibrate the left ventricular-only pacing therapy for a plurality of heart rates based on electrical inhomogeneity information (EHI) generated from the monitored electrical activity from the plurality of external electrodes during the left ventricular-only pacing therapy, calibrate the biventricular pacing therapy for a plurality of heart rates based on the EHI generated from the monitored electrical activity from the plurality of external electrodes during the biventricular pacing therapy, and deliver one or both of the calibrated left ventricular-only pacing therapy and the calibrated biventricular pacing therapy.
[0010] The above summary is not intended to describe each embodiment or every implementation of the present disclosure, which will be more fully understood when read in conjunction with the following detailed description and claims, and in conjunction with the accompanying drawings. [Brief description of the drawings]
[0011] [Figure 1] FIG. 1 is a diagram of an exemplary system including an electrode device, a display device, and a computing device. [Diagram 2] FIG. 1 is a diagram of an exemplary external electrode arrangement for measuring torso surface potentials. [Diagram 3] FIG. 1 is a diagram of an exemplary external electrode arrangement for measuring torso surface potentials. [Figure 4] FIG. 1 is a block diagram of an exemplary method of evaluating and configuring cardiac therapy. [Diagram 5] FIG. 1 is a block diagram of an exemplary method for implementing or delivering an adaptive cardiac therapy. [Figure 6]FIG. 1 is a diagram of an exemplary system including an exemplary implantable medical device (IMD). [Figure 7A] FIG. 7 is a diagram of the example IMD of FIG. [Figure 7B] 7B is an enlarged view of the distal end of the electrical lead disposed in the left ventricle of FIG. 7A. [Figure 8A] FIG. 8 is a block diagram of an exemplary IMD for the systems of FIGS. 6-7. [Figure 8B] FIG. 8 is another block diagram of an exemplary IMD (eg, implantable pulse generator) circuit and associated lead for use in the systems of FIGS. 6-7. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] In the following detailed description of exemplary embodiments, reference is made to the accompanying drawings which form a part hereof, and in which is shown, by way of illustration, specific embodiments which may be practiced. It is to be understood that other embodiments may be utilized and structural changes may be made without departing from (e.g., still within) the scope of the disclosure presented herein.
[0013] Exemplary systems, methods, and devices are described with reference to Figures 1-8. It will be apparent to one skilled in the art that elements or processes from one embodiment may be used in combination with elements or processes of other embodiments, and that possible embodiments of such systems, methods, and devices using combinations of features described herein are not limited to the specific embodiments shown in the figures and / or described herein. Furthermore, it will be recognized that the embodiments described herein may include many elements that are not necessarily shown to scale. Still further, it will be recognized that the timing of processes, and the sizes and shapes of various elements herein may be altered, and that certain timings, one or more shapes and / or sizes, or types of elements may be advantageous over others, yet still be within the scope of the present disclosure.
[0014] A number of electrocardiogram (ECG) signals (e.g., torso-surface potentials) can be measured or monitored using a number of external electrodes positioned around the surface or skin of a patient. The ECG signals can be used to evaluate and configure a cardiac therapy, such as, for example, a cardiac therapy provided by an implantable medical device implementing cardiac resynchronization therapy (CRT). As described herein, for example, the ECG signals can be collected or obtained non-invasively, since implantable electrodes cannot be used to measure ECG signals. Additionally, the ECG signals can be used to determine cardiac electrical activation times, which can be used to generate various metrics (e.g., electrical heterogeneity information) that can be used by a user (e.g., physician) to optimize one or more settings or parameters of a cardiac therapy (e.g., pacing therapy) such as CRT.
[0015] Various exemplary systems, methods, and graphical user interfaces can be configured to non-invasively assist a user (e.g., a physician) in assessing cardiac health and / or configuring (e.g., optimizing) cardiac therapy using an electrode apparatus including an external electrode, a display device, and a computing device. An exemplary system 100 including an electrode apparatus 110, a computing device 140, and a remote computing device 160 is shown in FIG.
[0016] As illustrated, the electrode device 110 includes multiple electrodes incorporated or contained within a band wrapped around the chest or torso of the patient 14. The electrode device 110 is operatively coupled to a computing device 140 (e.g., through a single or wired electrical connection, wirelessly, etc.) to provide an electrical signal from each of the electrodes to the computing device 140 for analysis, evaluation, etc. An exemplary electrode device may be described in U.S. Patent No. 9,320,446, entitled "Bioelectric Sensor Device and Methods," filed March 27, 2014, and issued March 26, 2016. Additionally, the exemplary electrode device 110 is described in more detail with reference to FIGS. 2 and 3.
[0017] Although not described herein, the exemplary system 100 may further include an imaging device. The imaging device may be any type of imaging device configured to image or provide an image of at least a portion of a patient in a non-invasive manner. For example, the imaging device may not use any components or parts that may be located within the patient to provide an image of the patient, except for non-invasive tools such as contrast agents. It should be understood that the exemplary systems, methods, and interfaces described herein may further use an imaging device to provide non-invasive assistance to a user (e.g., a physician) to position or place one or more pacing electrodes proximate to the patient's heart in conjunction with the configuration of a cardiac therapy.
[0018] For example, exemplary systems and methods can provide image-guided navigation that can be used to navigate leads, including electrodes, leadless electrodes, wireless electrodes, catheters, etc., within a patient's body while also providing non-invasive cardiac therapy configurations including determining effective or optimal pre-excitation intervals, such as AV and VV intervals. Exemplary systems and methods using imaging and / or electrode devices can be described in U.S. Patent Application Publication No. 2014 / 0371832 to Ghosh, published Dec. 18, 2014; U.S. Patent Application Publication No. 2014 / 0371833 to Ghosh et al., published Dec. 18, 2014; U.S. Patent Application Publication No. 2014 / 0323892 to Ghosh et al., published Oct. 30, 2014; and U.S. Patent Application Publication No. 2014 / 0323882 to Ghosh et al., published Oct. 20, 2014.
[0019] An exemplary imaging device may be configured to capture X-ray images and / or any other alternative imaging modality. For example, the imaging device may be configured to capture image or image data using isocentric fluoroscopy, biplane fluoroscopy, ultrasound, computed tomography (CT), multislice computed tomography (MSCT), magnetic resonance imaging (MRI), high frequency ultrasound (HIFU), optical coherence tomography (OCT), intravascular ultrasound (IVUS), two-dimensional (2D) ultrasound, three-dimensional (3D) ultrasound, four-dimensional (4D) ultrasound, intraoperative CT, intraoperative MRI, etc. It should further be understood that the imaging device may be configured to capture multiple consecutive images (e.g., sequentially) to provide video frame data. In other words, multiple images taken over time using the imaging device may provide video frame or movie data. Additionally, images may be acquired and displayed in two, three, or four dimensions. In more advanced forms, four-dimensional surface rendering of the heart or other regions of the body may also be achieved by incorporating cardiac or other soft tissue data from atlases, or preoperative imaging data captured by MRI, CT, or echocardiography. Image data sets from hybrid modalities, such as positron emission tomography (PET) in combination with CT, or single photon emission computed tomography (SPECT) in combination with CT, may also provide functional image data superimposed on the anatomical data, for example, to navigate an implantable device to a target location within the heart or other region of interest.
[0020] Systems and / or imaging devices that may be used in conjunction with the exemplary systems and methods described herein include, but are not limited to, U.S. Patent Application No. 2005 / 0008210 to Evron et al., published January 13, 2005; U.S. Patent Publication No. 2006 / 0074285 to Zarkh et al., published April 6, 2006; U.S. Patent No. 8,731,642 to Zarkh et al., issued May 20, 2014; U.S. Patent No. 8,861,830 to Brada et al., issued October 14, 2014; U.S. Patent No. 8,861,830 to Evron et al., published December 27, 2005; No. 6,980,675 to Nelson et al., U.S. Patent No. 7,286,866 to Okerlund et al., issued October 23, 2007, U.S. Patent No. 7,308,297 to Reddy et al., issued December 11, 2011, U.S. Patent No. 7,308,299 to Burrell et al., issued December 11, 2011, U.S. Patent No. 7,321,677 to Evron et al., issued January 22, 2008, U.S. Patent No. 7,346,381 to Okerlund et al., issued March 18, 2008, U.S. Patent No. 7,346,381 to Okerlund et al., issued November 11, 2008, No. 7,454,248 to Burrell et al. issued on May 18, 2009; U.S. Patent No. 7,499,743 to Vass et al. issued on March 3, 2009; U.S. Patent No. 7,565,190 to Okerlund et al. issued on July 21, 2009; U.S. Patent No. 7,587,074 to Zarkh et al. issued on September 8, 2009; U.S. Patent No. 7,599,730 to Hunter et al. issued on October 6, 2009; U.S. Patent No. 7,613,500 to Vass et al. issued on November 3, 2009; No. 7,742,629 to Zarkh et al. issued on June 22, 2010; U.S. Patent No. 7,747,047 to Okerlund et al. issued on June 29, 2010; U.S. Patent No. 7,778,685 to Evron et al. issued on August 17, 2010; U.S. Patent No. 7,778,686 to Vass et al. issued on August 17, 2010; U.S. Patent No. 7,813,785 to Okerlund et al. issued on October 12, 2010; U.S. Patent No. 7,996,817 to Vass et al. issued on August 9, 2011;No. 8,060,185 to Hunter et al., issued November 15, 2011, and U.S. Pat. No. 8,401,616 to Verard et al., issued March 19, 2013.
[0021] The computing device 140 and the remote computing device 160 may each include a display device 130, 160, respectively, that may be configured to display and analyze data, such as, for example, electrical signals (e.g., electrocardiogram data), electrical activation times, electrical heterogeneity information, etc. For example, one cardiac cycle or one cardiac beat of multiple cardiac cycles or beats represented by electrical signals collected or monitored by the electrode device 110 may be analyzed and evaluated for one or more metrics including, for example, activation times and electrical heterogeneity information that may be related to the therapeutic properties of one or more parameters related to cardiac therapy, such as pacing parameters, lead location, etc. More specifically, for example, the QRS complex of a single cardiac cycle may be evaluated for one or more metrics, such as QRS onset, QRS offset, QRS peak, electrical heterogeneity information (EHI), electrical activation time, standard deviation of left ventricular or thoracic electrical activation time (LVED), standard deviation of activation time (SDAT), mean left ventricular or thoracic surrogate electrical activation time (LVAT) relative to the earliest activation time, QRS duration (e.g., the interval between QRS onset and QRS offset), difference between mean left surrogate and mean right surrogate activation times, relative or absolute QRS morphology, difference between upper and lower percentile activation times (upper percentiles can be 90%, 80%, 75%, 70%, etc., and lower percentiles can be 10%, 15%, 20%, 25%, 30%, etc.), other statistical measures of central tendency (e.g., median or mode), variance (e.g., mean deviation, standard deviation, squared variance, interpercentile deviation, range), etc. Additionally, each of the one or more metrics may be location specific, for example, some metrics may be calculated from signals recorded or monitored from electrodes positioned around selected regions of the patient, such as the patient's left side, the patient's right side, etc.
[0022] In at least one embodiment, one or both of computing device 140 and remote computing device 160 may be a server, a personal computer, or a tablet computer. Computing device 140 may be configured to receive input from input device 142 (e.g., a keyboard) and send output to display device 130, and remote computing device 160 may be configured to receive input from input device 162 (e.g., a touch screen) and send output to display device 170. One or both of the computing apparatus 140 and the remote computing device 160 may include data storage that may allow access to processing programs or routines and / or one or more other types of data, for example, to analyze a plurality of electrical signals captured by the electrode apparatus 110, to determine QRS onset, QRS offset, median, mode, mean, peak or maximum, trough or minimum, to determine electrical activation time, to drive a graphical user interface configured to help a user non-invasively configure one or more pacing parameters or settings, such as, for example, pacing rate, ventricular pacing rate, AV interval, VV interval, pacing pulse width, pacing vector, multipoint pacing vector (e.g., left ventricular vector quad lead), pacing voltage, pacing configuration (e.g., biventricular pacing, right ventricular only pacing, left ventricular only pacing, etc.), and arrhythmia detection and treatment, rate adaptation settings and performance, etc.
[0023] The computing device 140 may be operably coupled to the input device 142 and the display device 130, e.g., to transmit data between each of the input device 142 and the display device 130, and the remote computing device 160 may be operably coupled to the input device 162 and the display device 170, e.g., to transmit data between each of the input device 162 and the display device 170. For example, the computing device 140 and the remote computing device 160 may be electrically coupled to the input devices 142, 162 and the display devices 130, 170 using, e.g., analog electrical connections, digital electrical connections, wireless connections, bus-based connections, network-based connections, Internet-based connections, etc. As described further herein, a user may provide input to the input devices 142, 162 to view and / or select one or more configuration information associated with, e.g., a cardiac therapy delivered by a cardiac therapy device, such as an implantable medical device.
[0024] As shown, input device 142 is a keyboard and input device 162 is a touch screen, however, it should be understood that input devices 142, 162 may include any device capable of providing input to computing apparatus 140 and computing device 160 to implement the functions, methods, and / or logic described herein. For example, input devices 142, 162 may include a keyboard, a mouse, a trackball, a touch screen (e.g., a capacitive touch screen, a resistive touch screen, a multi-touch touch screen, etc.), etc. Similarly, the display device 130, 170 may include any device capable of displaying information to a user, such as a graphical user interface 132, 172 including electrode status information, a graphical map of electrical activation, multiple signals of external electrodes over one or more heartbeats, QRS complexes, various cardiac therapy scenario selection regions, various rankings of cardiac therapy scenarios, various pacing parameters, electrical inhomogeneity information (EHI), textual instructions, an anatomical graphical representation of the human heart, an image or graphical representation of a patient's heart, a graphical representation of one or more electrode locations, a graphical representation of a human torso, an image or graphical representation of a patient's torso, a graphical representation or actual images of implanted electrodes and / or leads, etc. Additionally, the display device 130, 170 may include a liquid crystal display, an organic light emitting diode screen, a touch screen, a cathode ray tube display, etc.
[0025] The processing programs or routines stored and / or executed by the computing equipment 140 and the remote computing device 160 may include programs or routines for computational mathematics, matrix mathematics, decomposition algorithms, compression algorithms (e.g., data compression algorithms), calibration algorithms, image construction algorithms, signal processing algorithms (e.g., various filtering algorithms, Fourier transforms, fast Fourier transforms, etc.), standardization algorithms, comparison algorithms, vector mathematics, or other processing used to implement one or more of the example methods and / or processes described herein. Data stored and / or used by the computing device 140 and the remote computing device 160 may include, for example, electrical signal / waveform data (e.g., multiple QRS complexes) from the electrode device 110, electrical activation times from the electrode device 110, heart sound / signal / waveform data from an acoustic sensor, graphics (e.g., graphical elements, icons, buttons, windows, dialogs, pull-down menus, graphic areas, graphic regions, 3D graphics, etc.), graphical user interfaces, results of one or more processing programs or routines employed in accordance with the disclosure herein (e.g., electrical signals, electrical heterogeneity information, etc.), or any other data that may be used to implement one and / or more of the processes or methods described herein.
[0026] In one or more embodiments, the exemplary systems, methods, and interfaces may be implemented using one or more computer programs executing on a programmable computer, such as a computer including, for example, processing capability, data storage (e.g., volatile or non-volatile memory and / or storage elements), input devices, and output devices. The program code and / or logic described herein may be applied to input data to perform the functions described herein and generate desired output information. The output information may be applied as input to one or more other devices and / or methods as described herein or applied in a known manner.
[0027] One or more programs used to implement the systems, methods, and / or interfaces described herein may be provided using any programmable language, e.g., a high-level procedural and / or object-oriented programming language suitable for communicating with a computer system. Any such programs may be stored in any suitable device, e.g., a storage medium, readable by a general-purpose or special-purpose program that, when read by a device suitable for performing the procedures described herein, executes on a computer system (including, e.g., a processing device) for configuring and operating the computer system. In other words, in at least one embodiment, the exemplary systems, methods, and interfaces may be implemented using a computer-readable storage medium configured with a computer program, the storage medium thus configured causing a computer to operate in a particular predefined manner to perform the functions described herein. Furthermore, in at least one embodiment, the exemplary systems, methods, and interfaces may be described as being implemented by logic (e.g., object code) encoded in one or more non-transitory media that includes code for execution and that, when executed by a processor or processing circuitry, is operable to perform operations such as the methods, processes, and / or functions described herein.
[0028] The computing device 140 and the remote computing device 160 may be, for example, any fixed or mobile computer system (e.g., controller, microcontroller, personal computer, minicomputer, tablet computer, etc.). The exact configuration of the computing device 140 and the remote computing device 160 is not limiting, and essentially any device capable of providing suitable computing and control capabilities (e.g., mathematical functions such as signal analysis, median, mode, average, maximum value determination, minimum value determination, slope determination, minimum slope determination, maximum slope determination, graphics processing, etc.) may be used. As described herein, a digital file may be any medium (e.g., volatile or non-volatile memory, CD-ROM, punch cards, magnetic recordable tape, etc.) containing digital bits (e.g., encoded in binary, ternary, etc.) that may be readable and / or writable by the computing device 140 and the remote computing device 160 described herein. Also, as described herein, a file in user-readable format may be any representation of data (e.g., ASCII text, binary numbers, hexadecimal numbers, decimal numbers, graphics, etc.) presentable on any medium (e.g., paper, display, etc.) that is readable and / or understandable by a user.
[0029] In view of the above, it will be readily apparent that the functionality described in one or more embodiments according to the present disclosure may be implemented in any manner known to those skilled in the art. Thus, the computer language, computer system, or any other software / hardware used to implement the processes described herein does not limit the scope of the systems, processes, or programs described herein (e.g., the functionality provided by such systems, processes, or programs).
[0030] The exemplary electrode device 110 may be configured to measure body surface potentials of the patient 14, and more specifically, torso surface potentials of the patient 14. As shown in FIG. 2, the exemplary electrode device 110 may include a set or array of external electrodes 112, a strap 113, and an interface / amplifier circuit 116. The electrodes 112 may be attached or coupled to the strap 113, which may be configured to be wrapped around the torso of the patient 14 such that the electrodes 112 encircle the patient's heart. As further shown, the electrodes 112 may be positioned around the circumference of the patient 14, including in posterior, lateral, posterolateral, anterolateral, and anterior locations on the torso of the patient 14.
[0031] The exemplary electrode device 110 may be further configured to measure or monitor sounds from at least one or both of the patients 14. As shown in FIG. 2, the exemplary electrode device 110 may include a set or array of acoustic sensors 120 attached or coupled to a strap 113. The strap 113 may be configured to be wrapped around the torso of the patient 14 such that the acoustic sensors 120 encircle the patient's heart. As further shown, the acoustic sensors 120 may be positioned around the circumference of the patient 14, including at posterior, lateral, posterolateral, anterolateral, and anterior locations on the torso of the patient 14.
[0032] Additionally, the electrodes 112 and the acoustic sensor 120 may be electrically connected to the interface / amplifier circuit 116 via a wired connection 118. The interface / amplifier circuit 116 may be configured to amplify signals from the electrodes 112 and the acoustic sensor 120 and provide the signals to one or both of the computing device 140 and the remote computing device 160. Other exemplary systems may use a wireless connection to transmit signals sensed by the electrodes 112 and the acoustic sensor 120 to the interface / amplifier circuit 116 and then to one or both of the computing device 140 and the remote computing device 160, for example, as a channel of data. In one or more embodiments, the interface / amplifier circuit 116 may be electrically coupled to the computing device 140 using, for example, an analog electrical connection, a digital electrical connection, a wireless connection, a bus-based connection, a network-based connection, an internet-based connection, or the like.
[0033] In the example of FIG. 2, the electrode device 110 includes a strap 113, but in other examples, various mechanisms, e.g., any of tape or adhesives, may be used to aid in spacing and positioning of the electrodes 112 and acoustic sensor 120. In some examples, the strap 113 may include an elastic band, a strip of tape, or fabric. Additionally, in some examples, the strap 113 may be part of or integrated with a garment, such as, for example, a T-shirt. In other examples, the electrodes 112 and acoustic sensor 120 may be individually positioned on the torso of the patient 14. Additionally, in other examples, one or both of the electrodes 112 (e.g., arranged in an array) and the acoustic sensor 120 (e.g., also arranged in an array) may be part of or located within a patch, vest, and / or other method of securing the electrodes 112 and acoustic sensor 120 to the torso of the patient 14. Still further, in other examples, one or both of the electrodes 112 and acoustic sensor 120 may be part of or located within two sections of material or two patches. One of the two patches can be located on the front of the patient's 14 torso (e.g., to monitor electrical signals representative of the front of the patient's heart, measure surrogate cardiac electrical activation times representative of the front of the patient's heart, monitor or measure sounds on the front of the patient, etc.), and the other patch can be located on the back of the patient's 14 torso (e.g., to monitor electrical signals representative of the back of the patient's heart, measure surrogate cardiac electrical activation times representative of the back of the patient's heart, monitor or measure sounds on the back of the patient, etc.). In still further examples, one or both of the electrodes 112 and acoustic sensors 120 can be arranged in top and bottom rows that extend from the front of the patient 14 across the left side of the patient 14 to the front of the patient 14. In still further examples, one or both of the electrodes 112 and acoustic sensors 120 can be arranged in a curvilinear fashion around the underarm area, with the right chest having a less dense electrode / sensor density than the rest of the chest.
[0034] The electrodes 112 may be configured to surround the heart of the patient 14 and record or monitor electrical signals associated with cardiac depolarization and repolarization after the signals have propagated through the torso of the patient 14. Each of the electrodes 112 may be used in a unipolar configuration to sense torso surface potentials reflective of cardiac signals. The interface / amplifier circuit 116 may also be coupled to a return or indifferent electrode (not shown) that may be used in combination with each electrode 112 for unipolar sensing.
[0035] In some examples, there may be about 12 to about 50 electrodes 112 and about 12 to about 50 acoustic sensors 120 spatially distributed around the patient's torso. Other configurations may have more or fewer electrodes 112 and more or fewer acoustic sensors 120. It should be understood that the electrodes 112 and acoustic sensors 120 may not be arranged or distributed in an array that extends all around or completely around the patient 14. Instead, the electrodes 112 and acoustic sensors 120 may be arranged in an array that extends only partially around or partially around the patient 14. For example, the electrodes 112 and acoustic sensors 120 may be distributed on the anterior, posterior, and left side of the patient, with fewer or no electrodes and acoustic sensors proximate the right side (including the posterior and anterior regions of the patient's right side).
[0036] Computing device 140 can record and analyze torso-surface potential signals sensed by electrodes 112 and audio signals sensed by acoustic sensor 120, which are amplified / conditioned by interface / amplifier circuit 116. Computing device 140 can be configured to analyze the electrical signals from electrodes 112 to provide electrocardiogram (ECG) signals, information, or data from the patient's heart, as described further herein. Computing device 140 can be configured to analyze the electrical signals from acoustic sensor 120 to provide audio signals, information, or data from the patient's body and / or a device implanted therein (such as a left ventricular assist device).
[0037] Additionally, the computing device 140 and the remote computing device 160 can be configured to provide graphical user interfaces 132, 172 that show various information related to the electrode device 110 and data collected or sensed using the electrode device 110. For example, the graphical user interfaces 132, 172 can depict an ECG including a QRS complex obtained using the electrode device 110, and audio data including sound waves obtained using the acoustic sensor 120, as well as other information associated therewith. Exemplary systems and methods can non-invasively use the electrical information collected using the electrode device 110 and the audio information collected using the acoustic sensor 120 to assess the cardiac health of a patient and to assess and configure cardiac therapy delivered to the patient.
[0038] Additionally, the electrode device 110 may further include reference and / or drive electrodes positioned around the lower torso of the patient 14, for example, which may be further used by the system 100. For example, the electrode device 110 may include three reference electrodes, and signals from the three reference electrodes may be combined to provide a reference signal. Additionally, the electrode device 110 may use three caudal reference electrodes (e.g., instead of the standard references used in Wilson's coupling electrodes) to average the three caudally located reference signals to obtain a "true" unipolar signal with less noise.
[0039] 3 illustrates another exemplary electrode device 110 including a plurality of electrodes 112 configured to surround the heart of the patient 14 and record or monitor electrical signals associated with depolarization and repolarization of the heart after the signals have propagated through the torso of the patient 14, and a plurality of acoustic sensors 120 configured to surround the heart of the patient 14 and record or monitor audio signals associated with the heart after the signals have propagated through the torso of the patient 14. The electrode device 110 may include a vest 114 to which the plurality of electrodes 112 and the plurality of acoustic sensors 120 may be attached or to which the electrodes 112 and acoustic sensors 120 may be coupled. In at least one embodiment, the plurality of electrodes 112 or an array of electrodes 112 may be used to collect electrical information, such as, for example, surrogate electrical activation times. 2, the electrode device 110 of FIG 3 may include an interface / amplifier circuit 116 electrically coupled to each of the electrodes 112 and acoustic sensors 120 through wired connections 118 and configured to transmit signals from the electrodes 112 and acoustic sensors 120 to a computing device 140. As shown, the electrodes 112 and acoustic sensors 120 may be distributed throughout the torso of the patient 14, including, for example, at posterior, lateral, posterolateral, anterolateral, and anterior locations on the torso of the patient 14.
[0040] The vest 114 may be formed of fabric, and the electrodes 112 and acoustic sensors 120 may be attached to the fabric. The vest 114 may be configured to maintain the position and spacing of the electrodes 112 and acoustic sensors 120 on the torso of the patient 14. Additionally, the vest 114 may be marked to aid in determining the location of the electrodes 112 and acoustic sensors 120 on the surface of the torso of the patient 14. In some examples, there may be about 25 to about 256 electrodes 112 and about 25 to about 256 acoustic sensors 120 distributed around the torso of the patient 14, although other configurations may have more or fewer electrodes 112 and more or fewer acoustic sensors 120.
[0041] The exemplary systems and methods can be used to provide non-invasive assistance to a user in assessing a patient's cardiac health and / or in evaluating and configuring a cardiac therapy currently being delivered to the patient (e.g., by an implantable medical device, LVAD, etc.). For example, the exemplary systems and methods can be used to assist a user in configuring and / or adjusting the settings of one or more cardiac therapies, such as optimizing the AV interval or delay of a pacing therapy (e.g., left ventricular only or left univentricular pacing therapy) and the AV and VV intervals or delays of a pacing therapy (e.g., biventricular pacing therapy).
[0042] Further, it should be understood that the computing device 140 and the remote computing device 160 may be operably coupled to one another in a number of different ways to perform or execute the functions described herein. For example, in the illustrated embodiment, the computing device 140 may be operably coupled to the remote computing device 160 wirelessly, as indicated by a wireless signal line emanating therebetween. Furthermore, as opposed to a wireless connection, one or more of the computing device 140 and the remote computing device 160 may be operably coupled via one or more wired electrical connections.
[0043] An exemplary method 200 of assessing and configuring cardiac therapies is illustrated in FIG. 4. The exemplary method 200 may be generally described as being used in the non-invasive assessment and configuration (e.g., optimization) of cardiac therapies. The exemplary method 200 may be described as non-invasive because it does not use invasive devices to perform the assessment and configuration of the cardiac therapies. However, the cardiac therapies delivered may be described as invasive, such as when one or more pacing electrodes are implanted near the patient's heart. Thus, the exemplary method 200 may be used to assess and configure such invasive cardiac therapies.
[0044] The exemplary method 200 can be generally described as determining pacing settings for each of a left ventricular-only pacing therapy and a biventricular pacing therapy. Pacing settings can be determined for each of a plurality of different heart rates, for use by a pacing device, such as an IMD as described herein, to deliver adaptive cardiac therapies. For example, as shown in FIG. 4 and further described herein, the method 200 can determine AV and VV intervals for a plurality of different or a range of heart rates for use with a biventricular pacing therapy and determine AV intervals for a plurality of different or a range of heart rates for use with a left ventricular-only pacing therapy.
[0045] The exemplary method 200 may include monitoring or measuring electrical activity using a plurality of external electrodes 202. The plurality of external electrodes may be similar to the external electrodes provided by the electrode device 110, as described herein with respect to FIGS. 1-3. For example, the plurality of external electrodes may be part of or incorporated into a vest or band positioned around the patient's torso. More specifically, the plurality of electrodes may be described as surface electrodes positioned in an array that is configured to be positioned proximate to the skin of the patient's torso. The electrical activity monitored during the process 202 prior to delivery of cardiac therapy may be referred to as "baseline" electrical activity, since no therapy is delivered to the patient such that the patient's heart is in its natural or intrinsic rhythm.
[0046] The exemplary method 200 may include measuring or monitoring an intrinsic AV delay or conduction time of the patient's heart at a current heart rate 204. The intrinsic AV delay may be measured from a single intrinsic AV conduction time over a single cardiac cycle, or from a heart rate (e.g., 833 ms at a heart rate of 72 beats per minute). Additionally, the intrinsic AV delay may be the average, mode, median, and / or any other statistical metric of multiple measured intrinsic AV conduction times. For example, the intrinsic AV delay may be the average of the intrinsic AV delays of a selected heart rate at a selected heart rate. For example, a patient may have an average intrinsic AV delay of 200 ms measured over three heart beats at a heart rate of 70 beats per minute (bpm).
[0047] During or concurrently with the monitoring or acquisition of electrical activity 202, the exemplary method 200 can initiate delivery of a cardiac therapy 206, such as, for example, a left ventricular-only or left univentricular pacing therapy, or a biventricular pacing therapy. The cardiac therapy 206 may be delivered by at least one electrode configured to electrically stimulate (e.g., depolarize, pace, etc.) the patient's left ventricle after an atrial sense or pace in left ventricular-only pacing, or the patient's left and right ventricles after an atrial sense or pace in biventricular pacing. The cardiac therapy may be delivered to the left ventricle using an AV interval or delay, which is the time between an atrial event (e.g., a paced depolarization or an intrinsic depolarization) and a left ventricular pace, and the cardiac therapy may be delivered to the right ventricle using a VV interval or delay, which is the time between a left ventricular event (e.g., a paced depolarization or an intrinsic depolarization) and a right ventricular pace.
[0048] In at least one embodiment, each of the electrodes may be coupled to one or more leads implanted in or proximate to the patient's heart. Additionally, in at least one embodiment, the cardiac therapy 206 may be delivered by a leadless electrode. Exemplary cardiac therapies using implanted electrodes and leads may be further described herein with reference to FIGS. 6-8. Although the systems and devices of FIGS. 6-8 include three leads, it should be understood that the exemplary systems and methods described herein may be used with any type of cardiac pacing system, including no leads, fewer than three leads, and more than three leads. As described herein, the delivery of the cardiac therapy may be described as invasive, and the exemplary methods and systems may be described as non-invasive, since the exemplary methods and systems may only initiate and configure the delivery of the cardiac therapy, and the exemplary methods and systems may further use electrical signals that are non-invasively monitored or obtained from the patient. Additionally, exemplary cardiac therapies can utilize leaded or leadless implantable cardiac devices including tissue-piercing electrodes implantable from the triangle of Koch's area of the right atrium, through the right atrial endocardium and central fibrous body, to deliver cardiac therapy to or sense electrical activity of the left ventricular electrical activity of the basal and / or septal portions of the left ventricular myocardium of the patient's heart, as described in U.S. Provisional Patent Application No. 62 / 647,414, entitled "VfA CARDIAC THERAPY," filed March 23, 2018, and U.S. Provisional Patent Application No. 62 / 725,763, entitled "ADAPTIVE VfA CARDIAC THERAPY," filed August 31, 2018, each of which is incorporated herein by reference in its entirety.
[0049] The monitored electrical activity may be used to generate electrical inhomogeneity information (EHI) 208 of the current AV and / or VV intervals at the current heart rate. The EHI may be described as information or data representative of at least one of mechanical and electrical heart function. The EHI and other cardiac therapy information may be described in U.S. Provisional Patent Application No. 61 / 834,133, filed June 12, 2013, entitled "METRICS OF ELECTRICAL DYSSYNCHRONY AND ELECTRICAL ACTIVATION PATTERNS FROM SURFACE ECG ELECTRODES," which is incorporated herein by reference in its entirety.
[0050] Electrical heterogeneity information (e.g., data) may be defined as information indicative of at least one of cardiac mechanical synchrony or dyssynchrony and / or cardiac electrical synchrony or dyssynchrony. In other words, electrical heterogeneity information may represent a surrogate for the actual mechanical and / or electrical function of the patient's heart. In at least one embodiment, a relative change in electrical heterogeneity information (e.g., from baseline heterogeneity information to treatment heterogeneity information, from a first set of treatment heterogeneity information to a second set of treatment heterogeneity information, etc.) may be used to determine a surrogate value representative of a change in hemodynamic response (e.g., an abrupt change in LV pressure gradient). Left ventricular pressure may be invasively monitored using a pressure sensor typically located in the left ventricle of the patient's heart. Thus, using electrical heterogeneity information to determine a surrogate value representative of left ventricular pressure may avoid invasive monitoring using a left ventricular pressure sensor.
[0051] In at least one embodiment, the electrical heterogeneity information may include, for example, a standard deviation of ventricular activation times measured using some or all of the external electrodes of the electrode device 110. Additionally, the local or regional electrical heterogeneity information may include a standard deviation and / or average of activation times measured using electrodes located in a particular anatomical region of the torso. For example, local or regional left side electrical heterogeneity information may be calculated using external electrodes located on the left side of the patient's torso.
[0052] The electrical heterogeneity information can be generated using one or more of a variety of systems and / or methods. For example, the electrical heterogeneity information can be generated using an array or multiple surface electrodes and / or imaging systems, as described in U.S. Patent Application Publication No. 2012 / 0283587A1, entitled "ASSESSING INTRA-CARDIAC ACTIVATION PATTERNS AND ELECTRICAL DYSSYNCHRONY," published on November 8, 2012, U.S. Patent Application Publication No. 2012 / 0284003A1, entitled "ASSESSING INTRA-CARDIAC ACTIVATION PATTERNS," published on November 8, 2012, and U.S. Patent No. 8,180,428B2, entitled "METHODS AND SYSTEMS FOR USE IN SELECTING CARDIAC PACING SITES," published on May 15, 2012.
[0053] The electrical heterogeneity information may include one or more metrics or indices. For example, one of the metrics or indices of electrical heterogeneity may be the standard deviation of activation times (SDAT) measured using some or all of the electrodes on the surface of the patient's torso. In some examples, the SDAT may be calculated using estimated cardiac activation times on the surface of a model heart.
[0054] Another metric or indicator of electrical heterogeneity may be the left standard deviation of surrogate electrical activation times (LVED) monitored by external electrodes located proximate to the patient's left side. Additionally, another metric or indicator of electrical heterogeneity may include the mean of surrogate electrical activation times (LVAT) monitored by external electrodes located proximate to the patient's left side. LVED and LVAT may be determined (e.g., calculated, computed, etc.) from electrical activity measured only by electrodes located proximate to the patient's left side, which may be referred to as the "left" electrodes. A left electrode may be defined as any surface electrode located proximate to the left ventricle, including the area to the left of the patient's sternum and spine. In one embodiment, the left electrodes may include all anterior electrodes to the left of the sternum and all posterior electrodes to the left of the spine. In another embodiment, the left electrodes may include all anterior electrodes and all posterior electrodes to the left of the sternum. In yet another embodiment, the left electrodes may be designated based on the contours of the left and right sides of the heart as determined using an imaging device (e.g., x-ray, fluoroscopy, etc.).
[0055] Another exemplary metric or indicator of dyssynchrony may be the range of activation times (RAT), which may be calculated, for example, globally or for a region, as the difference between the maximum and minimum torso-surface or cardiac activation times. The RAT reflects the span of activation times, while the SDAT gives an estimate of the variance of activation times from the mean. The SDAT also provides an estimate of activation time heterogeneity, since if activation times are spatially heterogeneous, individual activation times will move further away from the mean activation time, indicating delayed activation of one or more regions of the heart. In some examples, the RAT may be calculated using estimated cardiac activation times on the surface of a model heart.
[0056] Another exemplary metric or index of electrical heterogeneity information may include an estimate of the percentage of surface electrodes located within a particular region of interest of the torso or heart where the activation time associated with the torso or heart is greater than a particular percentile, such as the 70th percentile, of the measured QRS complex duration or determined activation time of the surface electrodes. The region of interest may be, for example, the posterior, left anterior, and / or left ventricular regions. An exemplary metric, or index, may be referred to as percentage of late activation (PLAT). PLAT may be described as providing an estimate of the percentage of the posterior and left anterior regions associated with the region of interest, for example, the left ventricular region of the heart, that activate later. A higher value of PLAT may indicate a delay in activation of a significant portion of the region, for example, the left ventricle, and a potential benefit of electrical resynchronization through CRT, for example, by early excitation of the later regions of the left ventricle. In other examples, PLAT may be determined for other subsets of electrodes in other regions, such as the right anterior region, to assess delayed activation in the right ventricle. Additionally, in some examples, PLAT may be calculated using estimated cardiac activation times across the surface of a model heart, either for the entire heart or for a particular region of the heart, e.g., the left or right ventricle.
[0057] In one or more embodiments, the electrical heterogeneity information may include indicators of favorable changes in global cardiac electrical activation, for example, as described in Sweeney et al., "Analysis of Ventricular Activation Using Surface Electrocardiography to Predict Left Ventricular Reverse Volumetric Remodeling During Cardiac Resynchronization Therapy," Circulation, Feb. 9, 2010; 121(5):626-34, and / or Van Deursen et al., "Vectorcardiography as a Tool for Easy Optimization of Cardiac Resynchronization Therapy in Canine LBBB Hearts," Circulation Arrhythmia and Electrophysiology, Jun. 1, 2012; 5(3):544-52.The heterogeneity information may also include measurements of improved cardiac mechanical function as measured by imaging or other systems to track the movement of leads implanted within the heart, as described, for example, in Ryu et al., "Simultaneous Electrical and Mechanical Mapping Using 3D Cardiac Mapping System: Novel Approach for Optimal Cardiac Resynchronization Therapy," Journal of Cardiovascular Electrophysiology, February 2010, 21(2):219-22; Sperzel et al., "Intraoperative Characterization of Interventricular Mechanical Dyssynchrony Using Electroanatomic Mapping System-A Feasibility Study," Journal of Interventional Cardiac Electrophysiology, November 2012, 35(2):189-96; and / or U.S. Patent Application Publication No. 2009 / 0099619A1, published April 16, 2009, entitled "METHOD FOR OPTIMIZAING CRT THERAPY."
[0058] Additionally, although not shown in the block diagram of FIG. 4, electrical inhomogeneity information may be generated 208 for electrical activity monitored without cardiac therapy or prior to delivery of cardiac therapy, which may be referred to as baseline electrical inhomogeneity information.
[0059] Once electrical inhomogeneity information (EHI) 208 is generated for the current AV and / or VV intervals at the current heart rate, the exemplary method 200 may further adjust 210 one or both of the AV interval from the previous AV interval and the VV interval from the previous VV interval, depending on the therapy type, and return to delivering 206 left ventricular-only or biventricular pacing therapy and generating 208 the EHI from the monitored electrical activity.
[0060] For example, the AV and / or VV intervals may be adjusted (e.g., increased or decreased) by a step size value from a previous value. The AV and / or VV intervals may be described as being "swept" from an initial short AV and / or VV interval until an intrinsic ventricular event (e.g., depolarization) is sensed 212, e.g., the AV interval has been adjusted "too long". In at least one embodiment, the first or initial AV interval may be about 60 milliseconds (ms). The first or initial AV interval may be about 25 ms or more, about 35 ms or more, about 45 ms or more, about 55 ms or more, about 65 ms or more, about 75 ms or more, about 85 ms or more, etc. Additionally, the first or initial AV interval may be about 120 ms or less, about 100 ms or less, about 90 ms or less, about 80 ms or less, about 70 ms or less, about 60 ms or less, etc.
[0061] The AV interval may be increased by the step size until an intrinsic ventricular event is sensed 212. As used herein, an "intrinsic" ventricular event or conduction is one that occurs or is conducted naturally (e.g., across the AV node of the heart, from atrium to ventricle, etc.). In at least one embodiment, the step size or increment may be about 20 ms. The step size or increment may be about 5 ms or more, about 10 ms or more, about 15 ms or more, about 20 ms or more, about 25 ms or more, about 30 ms or more, about 45 ms or more, etc. Additionally, the step size or increment may be about 70 ms or less, about 60 ms or less, about 50 ms or less, about 40 ms or less, about 35 ms or less, about 30 ms or less, etc.
[0062] Thus, the exemplary method 200 may continue to deliver 206 left ventricular-only or biventricular pacing therapy, monitor 202 electrical activity, and generate 208 electrical inhomogeneity information for each adjusted AV and / or VV interval 210 until an intrinsic ventricular event is sensed 212. In other words, the method 200 may continue to repeat the same cycle (e.g., monitoring 202 electrical activity and generating 208 electrical inhomogeneity information) for different AV and / or VV intervals 210 until an intrinsic ventricular event is sensed 212.
[0063] Exemplary methods and systems may be described as initiating delivery of left univentricular or biventricular pacing therapy at a plurality of different AV and / or VV intervals 210 (e.g., a different AV interval each cycle) and monitoring electrical activity in each of the plurality of different AV and / or VV intervals at the current heart rate 202. Further, electrical inhomogeneity information indicative of at least one of mechanical and electrical heart function may be generated for each of the plurality of different AV and / or VV intervals in the current heart 208.
[0064] After an intrinsic ventricular event is sensed (e.g., after the AV interval becomes too “long” such that an intrinsic depolarization occurs before a ventricular pace can occur or be delivered according to the current AV interval) 212, the exemplary method 200 may select or identify an AV interval, and when delivering biventricular pacing, may also select or identify a VV interval based on the electrical heterogeneity information generated at the current heart rate 214. Thus, for a current or given heart rate, the exemplary method 200 will try or test a number of different pacing settings, e.g., AV intervals, VV intervals, using both left ventricular-only and biventricular pacing, to determine or select an AV interval to use with left ventricular-only pacing therapy at the current heart rate, and an AV interval and VV interval to use with biventricular pacing therapy at the current heart rate. The implantable medical device may be configured to use and utilize the selected pacing settings for use in providing adaptive pacing therapy in the current heart for which the pacing settings were evaluated and selected, as further described herein with reference to FIG. 5.
[0065] As described herein, the AV and / or VV intervals for the current heart rate can be selected using the EHI generated from the monitored electrical activity 214. For example, one or more EHI metrics described herein can be used alone or together to select the AV and / or VV intervals for the current heart rate. In one or more embodiments, the EHI metric that is indicative of the most effective cardiac therapy for the current heart rate can be selected. For example, the EHI metric SDAT can be used, and the AV and VV intervals that provide the SDAT that is indicative of the most effective cardiac therapy can be selected.
[0066] In one embodiment, the AV and / or VV interval that produced one or more of the minimum overall standard deviation (SDAT), minimum left standard deviation (LVED), and minimum left mean (LVAT) of surrogate electrical activation times may be identified. The identified AV and / or VV interval may be referred to as an optimal or optimized and / or effective AV and / or VV interval, for example, because the identified AV and / or VV interval may provide optimal and / or effective cardiac therapy at the current heart rate according to the generated heterogeneity information.
[0067] The exemplary method 200 can continue to determine and select pacing settings (AV intervals, VV intervals, etc.) for both left ventricular only and biventricular pacing across a number of different heart rates. As shown, the exemplary method 200 includes adjusting 216 the patient's heart rate and then returning a measurement of the intrinsic AV delay at the current heart rate.
[0068] The patient's heart rate can be adjusted in a number of different ways 216. For example, the patient can be instructed or induced to do or not do a particular amount of work or exercise (e.g., cycling in a supine position) to increase the patient's heart rate. For example, an implanted atrial pacing device can be used for atrial pacing to induce a number of different heart rates. Still further, the patient's heart rate can be titrated (e.g., increased or decreased) using controlled dosages of one or more drugs, such as, for example, beta blockers.
[0069] Optionally, for each selected or determined AV interval for each different heart rate, the method 200 may determine or generate 215 an AV interval adjustment value for each different heart rate based on the selected AV interval and the measured intrinsic AV interval. During delivery of cardiac pacing therapy, the AV interval adjustment value may be used to adjust the AV interval based on the sensed intrinsic AV delay, as described further herein. The AV interval adjustment value may be any suitable correction parameter that provides an optimal AV pacing delay depending on the measured intrinsic AV delay. In particular, the AV interval adjustment value may be associated with a heart rate and applied to the intrinsic AV delay measured at the corresponding heart rate.
[0070] In one embodiment, the AV interval adjustment value may be the difference between the selected AV interval and the measured intrinsic AV delay. In other words, the AV interval adjustment value may be described as an offset that may be applied to the measured intrinsic AV delay. For example, the offset may be added or subtracted from the measured intrinsic AV delay to arrive at the AV adjustment value. Non-limiting examples of offset AV interval adjustment values include approximately 0 ms, 10 ms, 20 ms, 30 ms, 40 ms, 50 ms, 60 ms, 70 ms, and 80 ms, either positive or negative (+ / -), and any suitable range between any of these. For example, if the measured intrinsic AV delay is approximately 220 ms and the AV adjustment value is 55 ms, the calculated optimal AV pacing interval applying the AV adjustment value will be 220 ms-55 ms=165 ms.
[0071] In one embodiment, the AV interval adjustment value may be a percentage of the selected AV interval relative to the measured intrinsic AV delay. In other words, the AV interval adjustment value is a percentage that can be applied to the measured intrinsic AV delay. For example, the percentage may be multiplied or divided by the measured intrinsic AV delay to arrive at the AV interval adjustment value. Non-limiting examples of percentage AV interval adjustment values include approximately 20 percent (%), 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100%, and any suitable range between any of these. For example, if the measured intrinsic AV delay is approximately 200 ms and the percentage AV adjustment value is 70%, the optimal AV pacing interval calculated by applying the percentage AV adjustment value is 200 ms x 70% = 140 ms.
[0072] Additionally, an EHI may be generated for a selected AV and VV interval of a biventricular cardiac therapy at the current heart rate and a selected AV interval of a left ventricular-only cardiac therapy at the current heart rate so that the EHIs for both therapies can be compared to determine which of the two therapies should be implemented at the current heart rate. 217 For example, if the EHI generated during a left ventricular-only cardiac therapy at the current heart rate indicates a cardiac therapy that is more effective than the biventricular cardiac therapy at the current heart rate, the left ventricular-only cardiac therapy can be selected for initial delivery to the patient at the current heart rate.
[0073] The selected or determined AV and VV interval information (e.g., selected AV and VV intervals, AV interval adjustments, etc.) for biventricular cardiac pacing therapy and AV interval information (e.g., selected AV, AV interval adjustments, etc.) for left ventricular only cardiac pacing therapy for each of a plurality of different heart rates may be stored (e.g., in a memory, a "look-up" table, etc.) for use by a cardiac therapy device such as an IMD. In this manner, the AV and / or VV interval information may be "looked up" or recalled based on the currently measured or monitored heart rate. In other words, AV and VV interval configuration information for use in providing adaptive therapy over a range of heart rates may be an outcome of the exemplary method 200, which may then be used by a cardiac therapy device to provide adaptive cardiac therapy, such as adaptive CRT.
[0074] An exemplary method 250 of implementing or delivering an adaptive cardiac therapy is shown in FIG. 5. The method 250 initially includes providing 252 pre-excitation intervals, such as selected AV and VV intervals for use at a plurality of different heart rates during biventricular pacing therapy and selected AV intervals for use at a plurality of different heart rates during left ventricular only pacing therapy. Such pre-excitation intervals may be provided or determined using the method 200 described herein with reference to FIG. 4 and may be used in the method 250 to provide the adaptive pacing therapy. The pre-excitation intervals may be provided 252 and programmed into the cardiac therapy device automatically by the exemplary systems and methods described herein and / or manually by a user using such exemplary systems and methods.
[0075] An exemplary method 250 may include pausing or stopping 254 ongoing pacing therapy, measuring 256 heart rate, and measuring 258 intrinsic AV delay or conduction time. Exemplary systems and methods for measuring or sampling intrinsic AV delay may be described in U.S. Patent No. 8,744,576, entitled "Sampling Intrinsic AV Conduction Time," issued June 3, 2014, and incorporated herein by reference in its entirety. As before, the intrinsic AV delay may be a single measured intrinsic AV delay over a single cardiac cycle, or the average, mode, median, and / or any other statistical metric of multiple measured intrinsic AV delays over multiple cardiac cycles.
[0076] Then, using the measured heart rate 256 and the measured intrinsic AV delay 258, the exemplary method 250 can adjust the AV and / or VV intervals of the pacing therapy according to the provided pre-excitation interval 260. In other words, the AV interval adjustment value of the measured heart rate and the measured intrinsic AV delay can be used to generate a new AV interval and / or the VV interval provided to the measured heart rate can be programmed as the new VV interval in biventricular pacing.
[0077] For example, if a patient's measured intrinsic AV delay was 200 ms at a heart rate of 90 bpm and the AV interval adjustment at 90 bpm was a difference ratio of 1.5, process 260 could generate a new AV interval of approximately 133 ms by dividing the measured intrinsic delay by the difference ratio.Further, for example, if a patient's measured intrinsic AV delay was 150 ms at a heart rate of 125 bpm and the AV interval adjustment at 125 bpm was a difference ratio of 1.5, process 260 could generate an AV interval of approximately 100 ms by dividing the measured intrinsic AV delay by the difference ratio.
[0078] Further, for example, if a patient's measured intrinsic AV delay was 200 ms at a heart rate of 100 bpm and the AV interval adjustment of 100 bpm was a difference term of 50 ms, process 260 could generate a new AV interval of approximately 150 ms by subtracting the difference term from the measured intrinsic AV delay. Further, for example, if a patient's measured intrinsic AV delay was 180 ms at a heart rate of 110 bpm and the AV interval adjustment of 110 bpm was a difference term of 60 ms, process 260 could generate a new AV interval of approximately 120 ms by subtracting the difference term from the measured intrinsic AV delay.
[0079] After the AV and / or VV intervals are generated or calculated 260, the AV and / or VV intervals can be evaluated to determine whether the generated AV and VV intervals should be used for cardiac therapy. For example, if the generated AV interval is "too long", the generated AV interval may not provide an effective and / or optimal pacing therapy to the patient. For example, the generated or calculated AV interval can be compared to a threshold, and if the AV interval is equal to or greater than the threshold, the AV interval cannot be used for cardiac therapy and the AV interval can be set to a nominal value (e.g., the sensed AV interval (SAV) can be set to 100 ms and the paced AV interval (PAV) can be set to 150 ms). Similarly, if the AV interval is less than the threshold, the AV interval can be used for cardiac therapy. The threshold can be about 200 ms or more, about 210 ms or more, about 220 ms or more, about 240 ms or more, about 250 ms or more, about 270 ms or more, about 300 ms or more, etc. Further, the threshold may be about 230 ms or less, about 260 ms or less, about 280 ms or less, about 310 ms or less, about 350 ms or less, about 370 ms or less, about 400 ms or less, etc. If the AV and VV intervals are determined to be acceptable for pacing therapy, such AV and VV intervals may be set or programmed in a cardiac therapy device (e.g., an IMD).
[0080] Pacing therapy may be resumed 262 and periodically, pacing therapy may be paused again 254 to adapt cardiac pacing therapy according to the current heart rate and the intrinsic measured AV delay. It should be appreciated that the frequency of pausing cardiac therapy and adapting cardiac pacing therapy may occur at any rate to provide effective cardiac pacing to the patient. In one embodiment, the period between adapting cardiac pacing and adapting cardiac pacing again may be every 1 minute. In other embodiments, the period between adapting cardiac pacing and adapting cardiac pacing again may be from about every 30 seconds to about every 15 minutes.
[0081] Additionally, the method 250 may further include a pacing type or configuration switching process 270. As shown, the patient's heart rate 272 and intrinsic AV delay 274 may be evaluated, and in response to such evaluation, the process 270 may switch 276 the pacing therapy before resuming 262 the pacing therapy.
[0082] The switching process 270 may switch from left ventricular only pacing therapy to biventricular pacing therapy or from biventricular pacing therapy to left ventricular only pacing therapy based on an evaluation 272 of the heart rate. In one embodiment, the heart rate may be evaluated by comparing the heart rate to a threshold heart rate switching value. More specifically, for example, if the heart rate exceeds the threshold heart rate switching value and the current pacing therapy is left ventricular only pacing, the pacing therapy may be switched to biventricular pacing, and conversely, if the heart rate is below the threshold heart rate switching value and the current pacing therapy is biventricular pacing, the pacing therapy may be switched to left ventricular only pacing. For example, if the heart rate is above 100 bpm and the current pacing configuration is left ventricular only, the device may switch to biventricular pacing.
[0083] Additionally, the switching process 270 may switch from left ventricular-only to biventricular pacing therapy or from biventricular to left ventricular-only pacing therapy based on an assessment 274 of the measured intrinsic AV delay. In one embodiment, the measured intrinsic AV delay may be assessed by comparing the measured intrinsic AV delay to an AV delay switching value. More specifically, for example, if the intrinsic AV delay exceeds the AV delay switching value and the current pacing therapy is left ventricular-only pacing, the pacing therapy may be switched to biventricular pacing, and conversely, if the intrinsic AV delay is less than the AV delay switching value and the current pacing therapy is biventricular pacing, the pacing therapy may be switched to left ventricular-only pacing. For example, if the patient's intrinsic AV exceeds a certain absolute value (e.g., about 300 ms to about 350 ms) or exceeds a certain threshold value (e.g., about 20 ms, about 30 ms, about 40 ms, etc.) compared to the baseline intrinsic AV delay and the current pacing configuration is left ventricular only, the device can switch to biventricular pacing 276.
[0084] Exemplary cardiac therapy systems and devices that may utilize the exemplary systems, interfaces, methods, and processes described herein with respect to Figures 1-5 may be further described herein with reference to Figures 6-8.
[0085] 6 is a conceptual diagram illustrating an exemplary therapy system 10 that may be used to deliver pacing therapy to a patient 14. The patient 14 may be, but is not necessarily, a human. The therapy system 10 may include an implantable medical device 16 (IMD) that may be coupled to leads 18, 20, 22. The IMD 16 may be, for example, an implantable pacemaker, cardioverter, and / or defibrillator that delivers or provides electrical signals (e.g., paces, etc.) to and / or senses electrical signals from the heart 12 of the patient 14 via electrodes coupled to one or more of the leads 18, 20, 22.
[0086] The leads 18, 20, 22 extend into the heart 12 of the patient 14 to sense electrical activity of the heart 12 and / or deliver electrical stimulation to the heart 12. In the example shown in Figure 6, the right ventricular (RV) lead 18 extends through one or more veins (not shown), the superior vena cava (not shown), and the right atrium 26 to the right ventricle 28. The left ventricular (LV) coronary sinus lead 20 extends through one or more veins, the vena cava, the right atrium 26, into the coronary sinus 30 to a region adjacent the free wall of the left ventricle 32 of the heart 12. The right atrial (RA) lead 22 extends through one or more veins and a vena cava into the right atrium 26 of the heart 12.
[0087] The IMD 16 can sense, among other things, electrical signals associated with depolarization and repolarization of the heart 12 via electrodes coupled to at least one of the leads 18, 20, 22. In some examples, the IMD 16 provides pacing therapy (e.g., pacing pulses) to the heart 12 based on the electrical signals sensed within the heart 12. The IMD 16 can be operable to adjust one or more parameters associated with the pacing therapy, such as, for example, AV delay and various other timings, pulse widths, amplitudes, voltages, burst lengths, etc. Additionally, the IMD 16 can be operable to deliver pacing therapy, which can be unipolar, bipolar, quadripolar, or even multipolar, using various electrode configurations. For example, a multipolar lead can include several electrodes that can be used to deliver pacing therapy. Thus, a multipolar lead system can provide or present multiple electrical vectors for pacing. The pacing vector may include at least one cathode, which may be at least one electrode located on at least one lead, and at least one anode, which may be at least one electrode located on at least one lead (e.g., the same lead, or a different lead) and / or on the casing or can of the IMD. Although improvement in cardiac function as a result of pacing therapy may depend primarily on the cathode, electrical parameters such as impedance, pacing threshold voltage, current drain, lifespan, etc. may further depend on the pacing vector, which includes both the cathode and the anode. The IMD 16 may also provide defibrillation and / or cardioversion therapy via electrodes located on at least one of the leads 18, 20, 22. Additionally, the IMD 16 may detect arrhythmias of the heart 12, such as fibrillation of the ventricles 28, 32, and deliver defibrillation therapy to the heart 12 in the form of electrical pulses. In some examples, the IMD 16 may be programmed to deliver a progression of therapy, e.g., pulses of increasing energy levels, until the fibrillation of the heart 12 is stopped.
[0088] 7A-7B are conceptual diagrams illustrating the IMD 16 and leads 18, 20, 22 of the therapy system 10 of FIG. 6 in greater detail. The leads 18, 20, 22 may be electrically coupled to a therapy delivery module (e.g., for delivery of pacing therapy), a sensing module (e.g., for sensing one or more signals from one or more electrodes), and / or any other module of the IMD 16 via a connector block 34. In some examples, the proximal ends of the leads 18, 20, 22 may include electrical contacts that electrically couple to respective electrical contacts in the connector block 34 of the IMD 16. Additionally, in some examples, the leads 18, 20, 22 may be mechanically coupled to the connector block 34 with the aid of set screws, contact pins, or another suitable mechanical coupling mechanism.
[0089] Each of the leads 18, 20, 22 includes an elongated insulative lead body that can carry multiple conductors (e.g., concentric coiled conductors, straight conductors, etc.) separated from one another by insulation (e.g., a tubular insulating sheath). In the illustrated example, bipolar electrodes 40, 42 are located proximate the distal end of lead 18. Additionally, bipolar electrodes 44, 45, 46, 47 are located proximate the distal end of lead 20, and bipolar electrodes 48, 50 are located proximate the distal end of lead 22.
[0090] Electrodes 40, 44, 45, 46, 47, 48 may take the form of ring electrodes, and electrodes 42, 50 may take the form of expandable spiral tip electrodes retractably mounted within insulated electrode heads 52, 54, 56, respectively. Each of electrodes 40, 42, 44, 45, 46, 47, 48, 50 may be electrically coupled to a respective one of the conductors (e.g., coiled and / or straight) within the lead body of the associated lead 18, 20, 22, and thereby to a respective one of the electrical contacts at the proximal end of lead 18, 20, 22.
[0091] Additionally, electrodes 44, 45, 46, and 47 are spaced apart by approximately 5.3 mm. 2 ~ approx. 5.8mm 21. The electrodes 44, 45, 46, and 47 may also be referred to as LV1, LV2, LV3, and LV4, respectively. The LV electrodes on the lead 20 (i.e., left ventricular electrode 1 (LV1) 44, left ventricular electrode 2 (LV2) 45, left ventricular electrode 3 (LV3) 46, and left ventricular electrode 4 (LV4) 47, etc.) may be spaced apart at variable distances. For example, electrode 44 may be at a distance of, for example, about 21 millimeters (mm) from electrode 45, electrodes 45 and 46 may be spaced apart from each other at a distance of, for example, about 1.3 mm to about 1.5 mm, and electrodes 46 and 47 may be spaced apart from each other at a distance of, for example, 20 mm to about 21 mm.
[0092] The electrodes 40, 42, 44, 45, 46, 47, 48, 50 may further be used to sense electrical signals (e.g., morphological waveforms in an electrogram (EGM)) associated with depolarization and repolarization of the heart 12. The electrical signals are conducted to the IMD 16 via the respective leads 18, 20, 22. In some examples, the IMD 16 may also deliver pacing pulses via the electrodes 40, 42, 44, 45, 46, 47, 48, 50 to cause depolarization of cardiac tissue of the patient's heart 12. In some examples, as shown in FIG. 7A, the IMD 16 includes one or more housing electrodes, such as a housing electrode 58, which may be integrally formed with an exterior surface of a housing 60 of the IMD 16 (e.g., a hermetically sealed housing) or otherwise coupled to the housing 60. Any of the electrodes 40, 42, 44, 45, 46, 47, 48, 50, in combination with the housing electrode 58, may be used for unipolar sensing or pacing. It is generally understood by those skilled in the art that other electrodes may be selected for defining or for use in pacing and sensing vectors. Additionally, any of the electrodes 40, 42, 44, 45, 46, 47, 48, 50, 58 may be used to sense electrical activity during pacing therapy when not being used to deliver pacing therapy.
[0093] As will be described in further detail with reference to FIG. 7A, the housing 60 can enclose a therapy delivery module that can include a stimulus generator for generating cardiac pacing pulses and defibrillation or cardioversion shocks, as well as a sensing module for monitoring the patient's heart's electrical signals (e.g., the patient's heart rhythm). The leads 18, 20, 22 can also include elongated electrodes 62, 64, 66, each of which can take the form of a coil. The IMD 16 can deliver defibrillation shocks to the heart 12 via any combination of the elongated electrodes 62, 64, 66 and the housing electrode 58. The electrodes 58, 62, 64, 66 can also be used to deliver cardioversion pulses to the heart 12. Additionally, the electrodes 62, 64, 66 can be fabricated from any suitable conductive material, such as, but not limited to, platinum, platinum alloys, and / or other materials known to be usable in implantable cardioversion electrodes. Because electrodes 62, 64, 66 are generally not configured to deliver pacing therapy, any of electrodes 62, 64, 66 may be used to sense electrical activity and may be used in combination with any of electrodes 40, 42, 44, 45, 46, 47, 48, 50, 58. In at least one embodiment, the RV elongated electrode 62 may be used to sense electrical activity of the patient's heart (e.g., in combination with the housing electrode 58, or a vector from the defibrillation electrode to the housing electrode) during delivery of pacing therapy.
[0094] The configuration of the exemplary treatment system 10 shown in FIGS. 6-8 is merely an example. In other examples, the treatment system may include epicardial leads and / or patch electrodes instead of or in addition to the transvenous leads 18, 20, 22 shown in FIG. 6. Furthermore, in other examples, the treatment system 10 may be implanted in / around the cardiac space without a transvenous lead (e.g., a leadless / wireless pacing system) or with a lead implanted in the left ventricle of the heart (e.g., implanted using a transvenous or approach) (in addition to or in place of a transvenous lead placed in the right ventricle of the heart as shown in FIG. 6). Furthermore, in one or more embodiments, the IMD 16 need not be implanted within the patient 14. For example, the IMD 16 may deliver various cardiac therapies to the heart 12 via percutaneous leads that extend through the skin of the patient 14 to various locations inside and outside the heart 12. In one or more embodiments, system 10 may utilize wireless pacing (e.g., using energy transfer to intracardiac pacing component(s) via ultrasound, inductive coupling, RF, etc.) and sensing of cardiac activation using electrodes on the can / housing and / or on subcutaneous leads.
[0095] In other examples of treatment systems for providing electrical stimulation therapy to heart 12, such treatment systems may include any suitable number of leads coupled to IMD 16, with each of the leads extending to any location within or proximate to heart 12. For example, other examples of treatment systems may include three transvenous leads positioned as shown in Figures 6-8. Still further, other treatment systems may include a single lead extending from IMD 16 into the right atrium 26 or right ventricle 28, or two leads extending into each of the right atrium 26 and right ventricle 28.
[0096] 8A is a functional block diagram of one exemplary configuration of the IMD 16. As shown, the IMD 16 may include a control module 81, a therapy delivery module 84 (which may include, for example, a stimulation generator), a sensing module 86, and a power source 90.
[0097] The control module or device 81 may include a processor 80, a memory 82, and a telemetry module or device 88. The memory 82 may include computer readable instructions that, for example, when executed by the processor 80, cause the IMD 16 and / or the control module 81 to perform various functions ascribed to the IMD 16 and / or the control module 81 described herein. Additionally, the memory 82 may include any volatile, non-volatile, magnetic, optical, and / or electrical media, such as random access memory (RAM), read only memory (ROM), non-volatile RAM (NVRAM), electrically erasable programmable ROM (EEPROM), flash memory, and / or other digital media. An exemplary capture management module may be a left ventricular capture management (LVCM) module described in U.S. Patent No. 7,684,863, entitled "LV THRESHOLD MEASUREMENT AND CAPTURE MANAGEMENT" and issued March 23, 2010.
[0098] The processor 80 of the control module 81 may include any one or more of a microprocessor, a controller, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), and / or equivalent discrete or integrated logic circuitry. In some examples, the processor 80 may include multiple components, such as any combination of one or more microprocessors, one or more controllers, one or more DSPs, one or more ASICs, and / or one or more FPGAs, as well as other discrete or integrated logic circuitry. The functionality attributed to the processor 80 herein may be embodied as software, firmware, hardware, or any combination thereof.
[0099] The control module 81 may control the therapy delivery module 84 to deliver therapy (e.g., electrical stimulation therapy such as pacing) to the heart 12 according to one or more selected therapy programs that may be stored in the memory 82. More specifically, the control module 81 (e.g., the processor 80) may control various parameters of the electrical stimulation delivered by the therapy delivery module 84, such as, for example, AV delay, VV delay, pacing pulses with amplitude, pulse width, frequency, or electrode polarity, which may be specified by one or more selected therapy programs (e.g., AV and / or VV delay adjustment program, pacing therapy program, pacing recovery program, capture management program, etc.). As illustrated, the therapy delivery module 84 is electrically coupled to the electrodes 40, 42, 44, 45, 46, 47, 48, 50, 58, 62, 64, 66, for example, via conductors in the respective leads 18, 20, 22 or, in the case of the housing electrode 58, via electrical conductors disposed within the housing 60 of the IMD 16. The therapy delivery module 84 may be configured to generate and deliver electrical stimulation therapy, such as pacing therapy, to the heart 12 using one or more of the electrodes 40 , 42 , 44 , 45 , 46 , 47 , 48 , 50 , 58 , 62 , 64 , 66 .
[0100] For example, the therapy delivery module 84 can deliver pacing stimuli (e.g., pacing pulses) via ring electrodes 40, 44, 45, 46, 47, 48 coupled to the leads 18, 20, 22 and / or the helical tip electrodes 42, 50 of the leads 18, 22. Further, for example, the therapy delivery module 84 can deliver defibrillation shocks to the heart 12 via at least two of the electrodes 58, 62, 64, 66. In some examples, the therapy delivery module 84 can be configured to deliver pacing, cardioversion, or defibrillation stimuli in the form of electrical pulses. In other examples, the therapy delivery module 84 can be configured to deliver one or more of these types of stimuli in the form of other signals, such as sine waves, square waves, and / or other substantially continuous time signals.
[0101] IMD 16 may further include a switch module 85, which the control module 81 (e.g., processor 80) can use to select, e.g., via a data / address bus, which of the available electrodes are used to deliver therapy, such as pacing pulses for pacing therapy, or which of the available electrodes are used for sensing. Switch module 85 may include a switch array, switch matrix, multiplexer, or any other type of switching device suitable for selectively coupling sensing module 86 and / or therapy delivery module 84 to one or more selected electrodes. More specifically, therapy delivery module 84 may include a plurality of pacing output circuits. Each pacing output circuit of the plurality of pacing output circuits may be selectively coupled, e.g., using switch module 85, to one or more of electrodes 40, 42, 44, 45, 46, 47, 48, 50, 58, 62, 64, 66 (e.g., a pair of electrodes for delivering therapy to a bipolar or multipolar pacing vector). In other words, each electrode can be selectively coupled to one of the pacing output circuits of the therapy delivery module using the switching module 85.
[0102] The sensing module 86 is coupled (e.g., electrically coupled) to sensing devices, which may include electrodes 40, 42, 44, 45, 46, 47, 48, 50, 58, 62, 64, 66 for monitoring electrical activity of the heart 12, e.g., electrocardiogram (ECG) / electrogram (EGM) signals, among other sensing devices. The ECG / EGM signals can be used to measure or monitor activation time (e.g., ventricular activation time), heart rate (HR), heart rate variability (HRV), heart rate irregularities (HRT), deceleration / acceleration capacity, deceleration sequence occurrence rate, T-wave alternans (TWA), P wave to P wave interval (also called PP interval or AA interval), R wave to R wave interval (also called RR interval or VV interval), P wave to QRS complex interval (also called PR interval, AV interval, or PQ interval), QRS complex morphology, ST segment (i.e., the segment connecting the QRS complex and the T wave), T wave changes, QT interval, electrical vector, and the like.
[0103] The switch module 85 may also be used in conjunction with the sensing module 86 to select which of the available electrodes to use or enable, for example, to sense the electrical activity of the patient's heart (e.g., one or more electrical vectors of the patient's heart using any combination of electrodes 40, 42, 44, 45, 46, 47, 48, 50, 58, 62, 64, 66). Similarly, the switch module 85 may also be used in conjunction with the sensing module 86 to select which of the available electrodes to not use (e.g., disable), for example, to sense the electrical activity of the patient's heart (e.g., one or more electrical vectors of the patient's heart using any combination of electrodes 40, 42, 44, 45, 46, 47, 48, 50, 58, 62, 64, 66), etc. In some examples, the control module 81 may select the electrodes to function as sense electrodes via a switch module in the sensing module 86, for example, by providing a signal over a data / address bus.
[0104] In some examples, the sensing module 86 includes channels that include amplifiers with relatively wider passbands than the R-wave or P-wave amplifiers. Signals from selected sense electrodes may be provided to a multiplexer and then converted by an analog-to-digital converter to a multi-bit digital signal for storage in memory 82, for example, as an electrogram (EGM). In some examples, storage of such EGMs in memory 82 may be under the control of direct memory access circuitry.
[0105] In some examples, the control module 81 may operate as an interrupt driven device and may respond to interrupts from the pacer timing and control module, which may correspond to the occurrence of sensed P-waves and R-waves and the generation of cardiac pacing pulses. Any necessary mathematical calculations may be performed by the processor 80, and any updates to values or intervals controlled by the pacer timing and control module may occur following such interrupts. A portion of the memory 82 may be configured as a number of recirculating buffers that may hold one or more series of measurement intervals that may be analyzed by the processor 80, for example, in response to the occurrence of a pace or sense interrupt to determine whether the patient's heart 12 is currently exhibiting an atrial or ventricular tachyarrhythmia.
[0106] The telemetry module 88 of the control module 81 may include any suitable hardware, firmware, software, or any combination thereof for communicating with another device, such as a programmer. For example, under the control of the processor 80, the telemetry module 88 may receive downlink telemetry from and transmit uplink telemetry to the programmer with the aid of an antenna, which may be internal and / or external. The processor 80 may provide data to be uplinked to the programmer and control signals for telemetry circuitry within the telemetry module 88, for example, via an address / data bus. In some examples, the telemetry module 88 may provide the received data to the processor 80 via a multiplexer.
[0107] The various components of the IMD 16 are further coupled to a power source 90, which may include rechargeable or non-rechargeable batteries. The non-rechargeable batteries can be selected to last for several years, while the rechargeable batteries can be inductively charged from an external device, for example, on a daily or weekly basis.
[0108] 8B is another embodiment of a functional block diagram of an IMD 16 depicting a bipolar RA lead 22, a bipolar RV lead 18, and a bipolar LVCS lead 20 coupled to an implantable pulse generator (IPG) circuit 31 without LACS pace / sense electrodes and having biventricular DDD / R type programmable modes and parameters known in the pacing art. The sensor signal processing circuit 91 in turn couples indirectly to a timing circuit 43 and to a microcomputer circuit 33 via a data and control bus. The IPG circuit 31 is generally shown in the functional block diagram divided into a microcomputer circuit 33 and a pacing circuit 21. The pacing circuit 21 includes a digital controller / timer circuit 43, an output amplifier circuit 51, a sense amplifier circuit 55, an RF telemetry transceiver 41, an activity sensor circuit 35, as well as several other circuits and components described below.
[0109] The crystal oscillator circuit 89 provides a basic timing clock for the pacing circuit 21 while the battery 29 is providing power. The power-on reset circuit 87 responds to an initial connection of the circuit to the battery to define an initial operating state, and similarly resets the device's operating state in response to detection of a low battery condition. The reference mode circuit 37 generates stable voltage references and currents for the analog circuitry in the pacing circuit 21. The analog-to-digital converter (ADC) and multiplexer circuit 39 digitizes analog signals and voltages to provide real-time telemetry of cardiac signals from the sense amplifier 55 for uplink transmission, e.g., via the RF transmitter and receiver circuit 41. The voltage reference and bias circuit 37, the ADC and multiplexer 39, the power-on reset circuit 87, and the crystal oscillator circuit 89 may correspond to any of those used in an exemplary implantable cardiac pacemaker.
[0110] When the IPG is programmed in a rate-responsive mode, signals output by one or more physiological sensors are used as rate control parameters (RCPs) to derive a physiological escape interval. For example, the escape interval is adjusted in proportion to the patient's activity level generated by a patient activity sensor (PAS) circuit 35 of the depicted exemplary IPG circuitry 31. The patient activity sensor 27 is coupled to the IPG housing and may take the form of a piezoelectric crystal transducer. The output signal of the patient activity sensor 27 may be processed and used as the RCP. The sensor 27 generates an electrical signal in response to sensed physical activity, which is processed by the activity circuitry 35 and provided to a digital controller / timer circuit 43. The activity circuit 35 and associated sensor 27 may correspond to the circuits disclosed in U.S. Pat. No. 5,052,388, entitled "METHOD AND APPARATUS FOR IMPLEMENTING ACTIVITY SENSING IN A PULSE GENERATOR," issued Oct. 1, 1991, and U.S. Pat. No. 4,428,378, entitled "RATE ADAPTIVE PACER," issued Jan. 31, 1984. Similarly, the exemplary systems, devices, and methods described herein may be practiced in conjunction with alternative types of sensors, such as oxygenation sensors, pressure sensors, pH sensors, and respiration sensors, for use in providing rate-responsive pacing functions. Alternatively, QT time may be used as a rate-indicating parameter, in which case no additional sensors are required. Similarly, the exemplary embodiments described herein may be practiced in non-rate-responsive pacemakers.
[0111] Data transmission to and from the external programmer is accomplished via a telemetry antenna 57 and associated RF transceiver 41, which serves both to demodulate received downlink telemetry and to transmit uplink telemetry. Uplink telemetry functions may include stored digital information, such as operating modes and parameters, EGM histograms, and other events, as well as real-time EGMs of atrial and / or ventricular electrical activity, and the ability to transmit marker channel pulses indicating the occurrence of depolarizations sensed and coordinated in the atria and ventricles.
[0112] Microcomputer 33 includes a microprocessor 80 and an associated system clock, as well as on-processor RAM and ROM chips 82A and 82B, respectively. Additionally, microcomputer circuit 33 includes a separate RAM / ROM chip 82C to provide additional memory capacity. Microprocessor 80 normally operates in a low power mode and is interrupt driven. Microprocessor 80 is awakened in response to defined interrupt events, which may include the A-TRIG, RV-TRIG, LV-TRIG signals generated by the timers of digital timer / controller circuit 43, and the A-EVENT, RV-EVENT, and LV-EVENT signals generated by sense amplifier circuit 55, among others. The particular values of the intervals and delays timed out by digital controller / timer circuit 43 are controlled by microcomputer circuit 33 via data and control buses from programmed parameter values and operating modes. Additionally, when programmed to operate as a rate-responsive pacemaker, timed interrupts, such as every period or every two seconds, may be provided to allow the microprocessor to analyze activity sensor data and update basic AA, VA, or VV escape intervals, as appropriate. Additionally, the microprocessor 80 can also serve to define variable operable AV delay intervals, VV delay intervals, and the energy delivered to each ventricle and / or atrium.
[0113] In one embodiment, microprocessor 80 is a custom microprocessor adapted to retrieve and execute instructions stored in RAM / ROM unit 82 in a conventional manner. However, it is contemplated that other implementations may be suitable for practicing the present disclosure. For example, an off-the-shelf, commercially available microprocessor or microcontroller, or custom application-specific hardwired logic, or state machine type circuitry, could perform the functions of microprocessor 80.
[0114] Digital controller / timer circuit 43 operates under the general control of microcomputer 33 to control timing and other functions within pacing circuit 21 and includes a set of timing and related logic circuits, certain of which are shown as being relevant to this disclosure. The timing circuits shown include a URI / LRI timer 83A, a VV delay timer 83B, an intrinsic interval timer 83C for timing the elapsed V-EVENT to V-EVENT interval or V-EVENT to A-EVENT interval or VV conduction interval, an escape interval timer 83D for timing the AV, VA, and / or VV pacing escape interval, an AV delay interval timer 83E for timing the A-LVp delay (or A-RVp delay) from the preceding A-EVENT or A-TRIG, a post-ventricular timer 83F for timing the post-ventricular period, and a date / time clock 83G.
[0115] The AV delay interval timer 83E is loaded with the appropriate delay interval for one ventricular chamber (e.g., either the A-RVp delay or the A-LVp) starting from the preceding A-PACE or A-EVENT until a timeout. The interval timer 83E triggers pacing stimulus delivery and can be based on one or more previous cardiac cycles (or from an empirically derived data set for a given patient).
[0116] The post-event timer 83F times out during the post-ventricular period following an RV-EVENT or LV-EVENT, or RV-TRIG or LV-TRIG, and during the post-atrial period following an A-EVENT or A-TRIG. The duration of the post-event period may also be selected as a programmable parameter stored in the microcomputer 33. The post-ventricular period includes PVARP, post-atrial ventricular blanking period (PAVBP), ventricular blanking period (VBP), post-ventricular atrial blanking period (PVARP), and ventricular refractory period (VRP), although other periods may be suitably defined depending at least in part on the operating circuitry employed in the pacing engine. The post-atrial period includes the atrial refractory period (ARP), during which the A-EVENT is ignored for purposes of resetting the AV delay, and the atrial blanking period (ABP), during which atrial sensing is disabled. It should be noted that the beginning of the post-atrial period and the AV delay may begin substantially simultaneously with the onset or end of each A-EVENT or A-TRIG, or, in the latter case, at the end of an A-PACE that may follow the A-TRIG. Similarly, the beginning of the post-ventricular period and the VA escape interval may begin substantially simultaneously with the onset or end of a V-EVENT or V-TRIG, or, in the latter case, at the end of a V-PACE that may follow the V-TRIG. Microprocessor 80 also optionally calculates an AV delay, a VV delay, a post-ventricular period, and a post-atrial period that vary with the sensor-based escape interval established as a function of the RCP(s) and / or the intrinsic atrial and / or heart rate.
[0117] Output amplifier circuit 51 includes an RA pace pulse generator (and an LA pace pulse generator if LA pacing is provided), an RV pace pulse generator, an LV pace pulse generator, and / or other pulse generators configured to provide atrial and ventricular pacing. To trigger generation of an RV-PACE or LV-PACE pulse, digital controller / timer circuit 43 generates an RV-TRIG signal upon timeout of an A-RVp delay (in the case of RV pre-excitation) or an LV-TRIG signal upon timeout of an A-LVp delay (in the case of LV pre-excitation) provided by AV delay interval timer 83E (or VV delay timer 83B). Similarly, digital controller / timer circuit 43 generates an RA-TRIG signal (or an LA-TRIG signal, if provided, which triggers output of an LA-PACE pulse) at the end of a VA escape interval timed by escape interval timer 83D.
[0118] Output amplifier circuit 51 includes switching circuitry for coupling selected pace electrode pairs from among the lead conductors and IND-CAN electrodes 20 to the RA pace pulse generator (and, if provided, the LA pace pulse generator), the RV pace pulse generator, and the LV pace pulse generator. Pace / sense electrode pair selection and control circuitry 53 selects which lead conductors and associated pace electrode pairs are coupled to atrial and ventricular output amplifiers in output amplifier circuit 51 to achieve RA, LA, RV, and LV pacing.
[0119] The sense amplifier circuit 55 includes sense amplifiers for pacing and sensing of the atrial and ventricular chambers. High impedance P-wave and R-wave sense amplifiers can be used to amplify the voltage difference signals generated across the sense electrode pairs by the passage of the cardiac depolarization wavefront. The high impedance sense amplifiers use high gain to amplify low amplitude signals and rely on passband filters, time domain filtering, and amplitude threshold comparisons to distinguish P-waves or R-waves from background electrical noise. The digital controller / timer circuit 43 controls the sensing settings of the atrial and ventricular sense amplifiers 55.
[0120] To avoid saturation of the sense amplifiers, the sense amplifiers may be disconnected from the sense electrodes during blanking periods before, during, and after delivery of a pace pulse to any of the pace electrodes of the pacing system. The sense amplifier circuit 55 includes blanking circuitry for disconnecting selected pairs of lead conductors and IND-CAN electrodes 20 from the inputs of the RA sense amplifier (and LA sense amplifier, if provided), RV sense amplifier, and LV sense amplifier during the ABP, PVABP, and VBP. The sense amplifier circuit 55 also includes switching circuitry for coupling selected sense electrode lead conductors and IND-CAN electrodes 20 to the RA sense amplifier (and LA sense amplifier, if provided), RV sense amplifier, and LV sense amplifier. Again, the sense electrode selection and control circuit 53 selects the conductors and associated sense electrode pairs to be coupled with the atrial and ventricular sense amplifiers in the output amplifier circuit 51 and the sense amplifier circuit 55 to achieve RA, LA, RV, and LV sensing along the desired unipolar and bipolar sensing vectors.
[0121] A right atrial depolarization or P-wave of the RA-SNESE signal sensed by the RA sense amplifier results in a RA-EVENT signal that is communicated to the digital controller / timer circuit 43. Similarly, a left atrial depolarization or P-wave of the LA-SNESE signal sensed by the LA sense amplifier, if provided, results in a LA-EVENT signal that is communicated to the digital controller / timer circuit 43. A ventricular depolarization or R-wave of the RV-SENSE signal is sensed by the ventricular sense amplifier and results in a RV-EVENT signal that is communicated to the digital controller / timer circuit 43. Similarly, a ventricular depolarization or R-wave of the LV-SNESE signal is sensed by the ventricular sense amplifier and results in a LV-EVENT signal that is communicated to the digital controller / timer circuit 43. The RV-EVENT, LV-EVENT, and RA-EVENT, LA-SENSE signals may be refractory or non-refractory and may be inadvertently caused by electrical noise signals or abnormally conducted depolarization waves rather than true R-waves or P-waves.
[0122] The techniques described in this disclosure, including those pertaining to IMD 16, computing device 140, and / or various constituent components, may be implemented, at least in part, in hardware, software, firmware, or any combination thereof. For example, various aspects of the techniques may be implemented in one or more processors, including one or more microprocessors, DSPs, ASICs, FPGAs, or any other equivalent integrated or discrete logic circuitry, as well as any combination of such components embodied in a programmer, such as a physician or patient programmer, a stimulator, a remote server, an image processing device, or other device. The terms "module," "processor," or "processing circuitry" may generally refer to any of the foregoing logic circuitry, alone or in combination with other logic circuitry, or any other equivalent circuitry.
[0123] Such hardware, software, and / or firmware may be implemented within the same device or within separate devices to support various operations and functions described in this disclosure. Furthermore, any of the described units, modules, or components may be implemented together or separately as separate but interoperable logical devices. The depiction of different functions as modules or units is intended to highlight different functional aspects and does not necessarily mean that such modules or units must be realized by separate hardware or software components. Rather, functionality associated with one or more modules or units may be performed by separate hardware or software components or may be integrated within a common or separate hardware or software component.
[0124] When implemented in software, the functionality attributed to the systems, devices, and techniques described in this disclosure may be embodied as instructions on a computer-readable medium, such as RAM, ROM, NVRAM, EEPROM, FLASH memory, magnetic data storage media, optical data storage media, etc. The instructions may be executed by a processing circuit and / or one or more processors to support one or more aspects of the functionality described in this disclosure. Exemplary embodiments
[0125] Embodiment 1: A system comprising: an electrode device comprising a plurality of external electrodes for monitoring electrical activity from the patient's tissue; a computing device comprising a processing circuit and coupled to the electrode device, the computing device comprising: monitoring the electrical activity of the patient's heart using one or more of the plurality of external electrodes during left ventricular-only pacing therapy delivered at a plurality of different AV intervals across a plurality of different heart rates and during biventricular pacing therapy delivered at a plurality of different AV and VV intervals across a plurality of different heart rates; generating electrical inhomogeneity information (EHI) from the monitored electrical activity from the electrode device, the EHI being indicative of one or both of mechanical and electrical cardiac function; selecting an AV interval for the left ventricular-only pacing therapy for each of the different heart rates based on the EHI generated from the monitored electrical activity during the left ventricular-only pacing therapy; and selecting AV and VV intervals for the biventricular pacing therapy for different heart rates based on an EHI generated from monitored electrical activity during the biventricular pacing therapy.
[0126] Embodiment 2: A method comprising: monitoring the electrical activity of the patient's heart using one or more of the plurality of external electrodes during left ventricular-only pacing therapy delivered at a plurality of different AV intervals and during biventricular pacing therapy delivered at a plurality of different AV and VV intervals across a plurality of different heart rates; generating electrical inhomogeneity information (EHI) from the monitored electrical activity from the electrode device, the EHI being indicative of one or both of mechanical and electrical cardiac function; selecting an AV interval for the left ventricular-only pacing therapy for each of the different heart rates based on the EHI generated from the monitored electrical activity during the left ventricular-only pacing therapy; selecting AV and VV intervals for the biventricular pacing therapy for different heart rates based on an EHI generated from monitored electrical activity during the biventricular pacing therapy.
[0127] Embodiment 3. A computing device comprising: Measuring an intrinsic AV delay during the absence of delivery of pacing therapy for each of the different heart rates; The system or method of any one of embodiments 1 and 2, further configured to: determine, for each different heart rate, an AV interval adjustment value for adjusting the AV interval based on an intrinsic AV delay sensed during delivery of the pacing therapy, wherein the AV interval adjustment for each different heart rate is based on the selected AV interval and the measured intrinsic AV delay corresponding to the different heart rates.
[0128] Embodiment 3. The system or method of embodiment 3, wherein determining the AV interval adjustment value for each different heart rate includes determining a difference between a selected AV interval and a measured intrinsic AV delay.
[0129] Embodiment 4. The system or method of embodiment 3, wherein determining the AV interval adjustment for each different heart rate includes determining a percentage of the selected AV interval relative to a measured intrinsic AV delay.
[0130] Embodiment 5. The system or method of any one of embodiments 1 to 4, wherein the controller is further configured to select left ventricular-only pacing therapy or biventricular pacing therapy as an initial pacing therapy diagnosis based on an EHI generated from the monitored electrical activity during left ventricular-only pacing therapy and the monitored electrical activity during biventricular pacing therapy.
[0131] Embodiment 6. A system or method according to any one of embodiments 1 to 5, wherein the EHI includes a metric of standard deviation of activation time (SDAT).
[0132] Embodiment 7. A system or method described in any one of embodiments 1 to 6, wherein the plurality of external electrodes comprises surface electrodes positioned in an array configured to be positioned adjacent to the patient's skin.
[0133] Embodiment 8. An implantable medical device comprising: a plurality of electrodes including an atrial pacing electrode, a left ventricular pacing electrode, and a right ventricular pacing electrode; a therapy delivery circuit operably coupled to the plurality of electrodes for delivering cardiac therapy to the patient's heart; a sensing circuit operably coupled to the plurality of electrodes for sensing electrical activity of the patient's heart; A controller comprising a processing circuit operably coupled to the therapy delivery circuit and the sensing circuit, the controller comprising: calibrating a left ventricular-only pacing therapy for a plurality of heart rates based on electrical heterogeneity information (EHI) generated from monitored electrical activity from a plurality of external electrodes during the left ventricular-only pacing therapy; calibrating a biventricular pacing therapy at a plurality of heart rates based on an EHI generated from the monitored electrical activity from the plurality of external electrodes during the biventricular pacing therapy; and a controller configured to deliver one or both of a calibrated left ventricular-only pacing therapy and a calibrated biventricular pacing therapy.
[0134] Embodiment 9. A method for delivering a calibrated left ventricular-only pacing therapy comprising: determining AV interval adjustments for each of the different heart rates; and delivering the calibrated left ventricular-only pacing therapy. Monitoring your heart rate; Measuring an intrinsic AV delay during the absence of delivery of pacing therapy; adjusting an AV interval of a calibrated left ventricular-only pacing therapy, a determined AV interval adjustment value corresponding to the monitored heart rate; and The device of embodiment 8, further comprising: adjusting the measured intrinsic AV delay using the measured intrinsic AV delay.
[0135] Embodiment 10. The device of embodiments 8 and 9, wherein the determined AV interval adjustment value comprises one of a difference between the selected AV interval and the measured intrinsic AV delay, and a percentage of the selected AV interval to the measured intrinsic AV delay.
[0136] Embodiment 11. The calibrated biventricular pacing therapy includes an AV interval adjustment value determined for each different heart rate and a VV interval adjustment value determined for each different heart rate, and delivering the calibrated biventricular pacing therapy includes: Monitoring your heart rate; Measuring an intrinsic AV delay during the absence of delivery of pacing therapy; adjusting an AV interval of a calibrated left ventricular-only pacing therapy, a determined AV interval adjustment value corresponding to the monitored heart rate; and adjusting for the measured intrinsic AV delay; and A device as described in embodiments 8 to 10, comprising: adjusting the VV interval of the calibrated biventricular-only pacing therapy using the determined VV interval adjustment value corresponding to the monitored heart rate.
[0137] Embodiment 12. A controller comprising: Monitoring your heart rate; A device as described in embodiments 8 to 11, further configured to switch from left ventricular-only pacing therapy to biventricular pacing therapy based on the monitored heart rate. Embodiment 13. A controller comprising: Measuring an intrinsic AV delay during the absence of delivery of pacing therapy; A device as described in embodiments 8 to 12, further configured to switch from left ventricular-only pacing therapy to biventricular pacing therapy based on the measured intrinsic AV delay.
[0138] This disclosure has been provided with reference to exemplary embodiments and is not intended to be construed in a limiting sense. As previously mentioned, those skilled in the art will recognize that various other exemplary applications can use the techniques described herein to take advantage of the beneficial properties of the apparatus and methods described herein. Various modifications of the exemplary embodiments, as well as additional embodiments of the present disclosure, will become apparent upon reference to this description.
Claims
1. 1. A system comprising: an electrode device comprising a plurality of external electrodes for monitoring electrical activity from the patient's tissue; a computing device coupled to the electrode device, the computing device comprising: monitoring electrical activity of the patient's heart using one or more of the plurality of external electrodes during left ventricular-only pacing therapy delivered at a plurality of different AV intervals across a plurality of different heart rates, and during biventricular pacing therapy delivered at a plurality of different AV and V-V intervals across a plurality of different heart rates; generating electrical inhomogeneity information (EHI) from the monitored electrical activity from the electrode device, the EHI being indicative of one or both of mechanical and electrical cardiac function; selecting an AV interval for a left ventricular-only pacing therapy for different heart rates based on the EHI generated from monitored electrical activity during the left ventricular-only pacing therapy; selecting AV and VV intervals for a biventricular pacing therapy for different heart rates based on the EHI generated from the monitored electrical activity during the biventricular pacing therapy; switching from a left ventricular-only pacing therapy to a biventricular pacing therapy or from a biventricular pacing therapy to a left ventricular-only pacing therapy based on an evaluation of the currently measured heart rate or an evaluation of a measured intrinsic AV delay. A system configured to:
2. the computing device comprising: measuring an intrinsic AV delay during the absence of delivery of pacing therapy for each of the different heart rates; 2. The system of claim 1, further configured to: determine, for each different heart rate, an AV interval adjustment value for adjusting the AV interval based on an intrinsic AV delay sensed during delivery of pacing therapy, wherein the AV interval adjustment for each different heart rate is based on the selected AV interval and the measured intrinsic AV delay corresponding to the different heart rates.
3. 3. The system of claim 2, wherein determining the AV interval adjustment for each different heart rate comprises determining a difference between the selected AV interval and the measured intrinsic AV delay.
4. 3. The system of claim 2, wherein determining the AV interval adjustment for each different heart rate comprises determining a percentage of the selected AV interval relative to the measured intrinsic AV delay.
5. 2. The system of claim 1, wherein the computing device is further configured to select a left ventricular-only pacing therapy or a biventricular pacing therapy as an initial pacing therapy diagnosis based on the EHI generated from the monitored electrical activity during left ventricular-only pacing therapy and the monitored electrical activity during biventricular pacing therapy.
6. The system of claim 1 , wherein the EHI includes a metric of standard deviation of activation times (SDAT).
7. The system of claim 1 , wherein the plurality of external electrodes comprises surface electrodes positioned in an array configured to be positioned adjacent to the patient's skin.
8. The system of claim 1, wherein the switching includes switching the pacing therapy to the biventricular pacing therapy when the heart rate exceeds a threshold heart rate switching value and the current pacing therapy is left ventricular-only pacing therapy.
Citation Information
Patent Citations
Cardiac stimulation in large ventricular wall stress areas
JP2008514373A
Biventricular triggered pacing for multi-site ventricular pacing
JP2014502538A
Closed loop optimization of control parameters during cardiac pacing
US20140277233A1
Systems and methods for configuration of interventricular interval
US20160045737A1
Systems and methods for configuration of atrioventricular interval
US20160045738A1
